Global Blood Gas and Electrolyte Analyzers Market to Reach USD 985 Million by 2026
By LabMedica International staff writers Posted on 30 Jun 2021 |

Illustration
The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 5.1% from an estimated USD 728.7 million in 2020 to USD 985 million by 2026, driven by improving infrastructure in diagnostic centers, hospitals and clinical laboratories, and a rise in the integration of critical equipment such as analyzers in ICUs, NICUs, and emergency and trauma units.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- Quanterix Completes Acquisition of Akoya Biosciences
- Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
- AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
- Illumina Acquires SomaLogic to Accelerate Proteomics Business
- Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
- QIAGEN and Incyte Enter into Precision Medicine Collaboration
- bioMérieux Acquires Day Zero Diagnostics Solutions and Technologies
- Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic
- Fujirebio Collaborates with Stanford Medicine to Advance Infectious Disease Research
- QuidelOrtho to Acquire MDx Company LEX Diagnostics
- QIAGEN Enters into New Strategic Partnerships for Expanding MRD Testing Portfolio in Oncology
- Danaher and AstraZeneca Partner on Next Generation AI-Powered Diagnostics
- EuroMedLab 2025 Showcases Latest Technologies and Innovations in Laboratory Medicine
- Qiagen Acquires NGS Analysis Software Company Genoox
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more